Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

NCT03004833 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Nivolumab
DRUG: Adriamycin
DRUG: Vinblastine
DRUG: Dacarbazine

Sponsor

University of Cologne